Why it matters: Dronedarone was originally approved to prevent recurrence of atrial fibrillation, or to lower the heart rate in adults who have had or have non-permanent atrial fibrillation. In September 2011 this indication was restricted to the maintenance of normal heart rhythm in ‘persistent’ or ‘paroxysmal’ atrial fibrillation after normal heart rhythm has been restored. NICE clinical guideline on Atrial Fibrillation puts greater emphasis on rate rather than rhythm control and has clarified the place of dronedarone in the treatment pathway.
This measure is currently under consultation. More details can be found on the NHS England website.
Description: Cost of Dronedarone per 1000 patients
CCGs are ordered by mean percentile over the past six months. Each chart shows the results for the individual CCG, plus deciles across all CCGs in the NHS in England.